Filter

Refine by date

—

Refine by collections

  • Print
  • Save

Search Results

You are looking at 1 - 5 of 5 items for :

  • "TSHR-blocking antibodies" x
Clear All
Tanja Diana Molecular Thyroid Research Laboratory, Department of Medicine I, Johannes Gutenberg University (JGU) Medical Center, Mainz, Germany

Search for other papers by Tanja Diana in
Google Scholar
PubMed Close
,
Hans-Peter Holthoff AdvanceCor GmbH, Martinsried, Germany

Search for other papers by Hans-Peter Holthoff in
Google Scholar
PubMed Close
,
Julia Fassbender AdvanceCor GmbH, Martinsried, Germany

Search for other papers by Julia Fassbender in
Google Scholar
PubMed Close
,
Christian Wüster Endocrine Laboratory and Practice Prof. Wüster, Mainz, Germany

Search for other papers by Christian Wüster in
Google Scholar
PubMed Close
,
Michael Kanitz Molecular Thyroid Research Laboratory, Department of Medicine I, Johannes Gutenberg University (JGU) Medical Center, Mainz, Germany

Search for other papers by Michael Kanitz in
Google Scholar
PubMed Close
,
George J. Kahaly Molecular Thyroid Research Laboratory, Department of Medicine I, Johannes Gutenberg University (JGU) Medical Center, Mainz, Germany

Search for other papers by George J. Kahaly in
Google Scholar
PubMed Close
, and
Martin Ungerer AdvanceCor GmbH, Martinsried, Germany

Search for other papers by Martin Ungerer in
Google Scholar
PubMed Close

and thyroid-related antibodies. Bioassay for Blocking TSHR Antibodies Levels of serum TSHR-blocking antibodies (TBAb) were measured according to the manufacturer’s (Quidel, San Diego, USA) instructions for the CE-marked cell-based bioassay [ 27

Article Type:
Research Article
DOI:
https://doi.org/10.1159/000508790
Volume/Issue:
Volume 9: Issue 1_Suppl
Free access
Susanne Neumann Laboratory of Endocrinology and Receptor Biology, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health Bethesda, Bethesda, Maryland, USA

Search for other papers by Susanne Neumann in
Google Scholar
PubMed Close
,
Christine C. Krieger Laboratory of Endocrinology and Receptor Biology, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health Bethesda, Bethesda, Maryland, USA

Search for other papers by Christine C. Krieger in
Google Scholar
PubMed Close
, and
Marvin C. Gershengorn Laboratory of Endocrinology and Receptor Biology, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health Bethesda, Bethesda, Maryland, USA

Search for other papers by Marvin C. Gershengorn in
Google Scholar
PubMed Close

by blocking the binding of GO-Igs to the extracellular domain of TSHR. A human monoclonal TSHR-blocking antibody, K1–70 [ 20 ], is being studied as a potential treatment for GD [ 21 ]. It was shown to be effective in vivo causing biochemical

Article Type:
Review Article
DOI:
https://doi.org/10.1159/000511538
Volume/Issue:
Volume 9: Issue 1_Suppl
Free access
Joanna Bogusławska Centre of Postgraduate Medical Education, Department of Biochemistry and Molecular Biology, Warsaw, Poland

Search for other papers by Joanna Bogusławska in
Google Scholar
PubMed Close
,
Marlena Godlewska Centre of Postgraduate Medical Education, Department of Biochemistry and Molecular Biology, Warsaw, Poland

Search for other papers by Marlena Godlewska in
Google Scholar
PubMed Close
,
Ewa Gajda Centre of Postgraduate Medical Education, Department of Biochemistry and Molecular Biology, Warsaw, Poland

Search for other papers by Ewa Gajda in
Google Scholar
PubMed Close
, and
Agnieszka Piekiełko-Witkowska Centre of Postgraduate Medical Education, Department of Biochemistry and Molecular Biology, Warsaw, Poland

Search for other papers by Agnieszka Piekiełko-Witkowska in
Google Scholar
PubMed Close

develop hypothyroidism due to the TSHR-blocking antibodies ( 1 , 2 ). Of note, hypothyroidism in GD patients can be observed as a short-term effect of the blocking autoantibodies, as well as a longer effect due to eventual autoimmune thyroid destruction

Article Type:
Review Article
Collections:
Thyroid autoimmunity
DOI:
https://doi.org/10.1530/ETJ-21-0024
Volume/Issue:
Volume 11: Issue 1
Open access
Luigi Bartalena Department of Clinical and Experimental Medicine, University of Insubria, Varese, Italy

Search for other papers by Luigi Bartalena in
Google Scholar
PubMed Close

between the two conditions [ 81 ]. Given of the important role of TSHR autoantibodies in causing hyperthyroidism due to Graves' disease and, probably, contributing to the pathogenesis of GO, future treatment might be represented by TSHR-blocking antibodies

Article Type:
Review Article
DOI:
https://doi.org/10.1159/000356042
Volume/Issue:
Volume 2: Issue 4
Free access
Christiaan F Mooij Department of Pediatric Endocrinology, Emma Children’s Hospital, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, the Netherlands

Search for other papers by Christiaan F Mooij in
Google Scholar
PubMed Close
,
Timothy D Cheetham Translational and Clinical Research Institute, Newcastle University, Newcastle-upon-Tyne, UK
Department of Pediatric Endocrinology, Royal Victoria Infirmary, Newcastle-upon-Tyne, UK

Search for other papers by Timothy D Cheetham in
Google Scholar
PubMed Close
,
Frederik A Verburg Department of Radiology and Nuclear Medicine, Erasmus MC, Rotterdam, the Netherlands

Search for other papers by Frederik A Verburg in
Google Scholar
PubMed Close
,
Anja Eckstein Department of Ophthalmology, University Duisburg Essen, Essen, Germany

Search for other papers by Anja Eckstein in
Google Scholar
PubMed Close
,
Simon H Pearce Translational and Clinical Research Institute, Newcastle University, Newcastle-upon-Tyne, UK
Endocrine Unit, Royal Victoria Infirmary, Newcastle-upon-Tyne, UK

Search for other papers by Simon H Pearce in
Google Scholar
PubMed Close
,
Juliane Léger Department of Pediatric Endocrinology and Diabetes, Reference Center for Rare Endocrine Growth and Development Diseases, Endo-ERN HCP, Assistance Publique-Hôpitaux de Paris, Robert Debré University Hospital, University of Paris, NeuroDiderot Institut National de la Santé et de la Recherche Médicale (INSERM), Paris, France

Search for other papers by Juliane Léger in
Google Scholar
PubMed Close
, and
A S Paul van Trotsenburg Department of Pediatric Endocrinology, Emma Children’s Hospital, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, the Netherlands

Search for other papers by A S Paul van Trotsenburg in
Google Scholar
PubMed Close

of further ATD. Is there a role for new treatment modalities like immune modulation in the treatment of pediatric GD? There are case reports and series describing the clinical course of adult patients receiving biologics like rituximab or TSHR-blocking

Article Type:
Other
Collections:
Pediatric thyroid diseases
DOI:
https://doi.org/10.1530/ETJ-21-0073
Volume/Issue:
Volume 11: Issue 1
Open access